BRPI0509482A - complexo compreendendo piroxicam, uma ciclodextrina e a arginina, processo de preparação de um complexo, composição farmacêutica, processo de preparação de um composto de inclusão solúvel, e composto de inclusão solúvel - Google Patents

complexo compreendendo piroxicam, uma ciclodextrina e a arginina, processo de preparação de um complexo, composição farmacêutica, processo de preparação de um composto de inclusão solúvel, e composto de inclusão solúvel

Info

Publication number
BRPI0509482A
BRPI0509482A BRPI0509482-8A BRPI0509482A BRPI0509482A BR PI0509482 A BRPI0509482 A BR PI0509482A BR PI0509482 A BRPI0509482 A BR PI0509482A BR PI0509482 A BRPI0509482 A BR PI0509482A
Authority
BR
Brazil
Prior art keywords
complex
inclusion compound
soluble inclusion
preparing
piroxicam
Prior art date
Application number
BRPI0509482-8A
Other languages
English (en)
Inventor
Bernard Freiss
Florence Marciacq
Hubert Lochard
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0403450A external-priority patent/FR2868315B1/fr
Priority claimed from FR0411201A external-priority patent/FR2876911B1/fr
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of BRPI0509482A publication Critical patent/BRPI0509482A/pt
Publication of BRPI0509482B1 publication Critical patent/BRPI0509482B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

COMPLEXO COMPREENDENDO PIROXICAM, UMA CICLODEXTRINA E A ARGININA, PROCESSO DE PREPARAçãO DE UM COMPLEXO, COMPOSIçãO FARMACêUTICA, PROCESSO DE PREPARAçãO DE UM COMPOSTO DE INCLUSãO SOLUVEL, E COMPOSTO DE INCLUSãO SOLúVEL A presente invenção refere-se a um processo de preparação de um composto de inclusão solúvel compreendendo uma ou várias substâncias ativas pouco solúveis em um meio aquoso, incluídas em uma ou várias moléculas hospedeiras, caracterizado em que ele compreende as etapas sucessivas seguintes: (a) colocação em contato de uma ou várias substâncias ativas com uma ou várias moléculas hospedeiras, (b) realização de uma etapa de difusão molecular por colocação em contato, em modo estático, de um fluido denso sob pressão com a mistura obtida na etapa (a) em presença de um ou vários agentes de difusão, (e) recuperação do complexo molecular substância ativa - molécula hospedeira assim formado, (d) realização de uma etapa que consiste em acrescentar e misturar um agente de interação com o complexo ao complexo molecular substância ativa - moléculas hospedeiras, (e) recuperação do composto de inclusão solúvel assim formado. Ela refere-se igualmente ao composto de inclusão solúvel susceptível de ser obtido por este processo, particularmente um complexo piroxicam- ciclodextrina- arginina.
BRPI0509482-8A 2004-04-01 2005-03-29 complexo de inclusão, processo de preparação de um complexo de inclusão, e composição farmacêutica BRPI0509482B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FR0403450A FR2868315B1 (fr) 2004-04-01 2004-04-01 Procede de preparation d'un compose d'inclusion soluble de substances actives dans une molecule hote avec l'aide d'un agent d'interaction par fluide supercritique
FR0403450 2004-04-01
FR0411201A FR2876911B1 (fr) 2004-10-21 2004-10-21 Complexe comprenant du piroxicam, une cyclodextrine et de l'arginine
FR0411201 2004-10-21
PCT/FR2005/000739 WO2005097201A2 (fr) 2004-04-01 2005-03-29 Complexes d’inclusions comprenant du piroxicam, une cyclodextrine et l’arginine

Publications (2)

Publication Number Publication Date
BRPI0509482A true BRPI0509482A (pt) 2007-09-11
BRPI0509482B1 BRPI0509482B1 (pt) 2018-12-11

Family

ID=34968371

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509482-8A BRPI0509482B1 (pt) 2004-04-01 2005-03-29 complexo de inclusão, processo de preparação de um complexo de inclusão, e composição farmacêutica

Country Status (16)

Country Link
US (2) US8461133B2 (pt)
EP (2) EP2260871B1 (pt)
JP (1) JP5091661B2 (pt)
AR (1) AR049488A1 (pt)
AT (1) ATE504316T1 (pt)
BR (1) BRPI0509482B1 (pt)
CA (1) CA2563101C (pt)
CY (1) CY1114198T1 (pt)
DE (1) DE602005027333D1 (pt)
DK (1) DK2260871T3 (pt)
ES (1) ES2424235T3 (pt)
PL (2) PL2260871T3 (pt)
PT (2) PT2260871E (pt)
RU (1) RU2382654C2 (pt)
SI (1) SI2260871T1 (pt)
WO (1) WO2005097201A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2876910B1 (fr) 2004-10-21 2007-04-13 Pierre Fabre Medicament Sa Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction
FR2876914A1 (fr) * 2004-10-21 2006-04-28 Pierre Fabre Medicament Sa Complexe comprenant un antibiotique, une cyclodextrine et un agent d'interaction
FR2914187B1 (fr) * 2007-03-28 2011-01-21 Pf Medicament Complexes d'ibuprofene, de cyclodextrines et d'agents ternaires, et leurs utilisations en pharmaceutique.
US20120171184A1 (en) 2010-12-31 2012-07-05 Lajos Szente Cellular hydration compositions
KR101383941B1 (ko) 2012-03-09 2014-04-10 동아에스티 주식회사 피록시캄 또는 약제학적으로 허용되는 그의 염과 히알루론산 또는 약제학적으로 허용되는 그의 염의 안정한 액상 조성물 및 그 제조방법
US10532102B2 (en) 2016-08-19 2020-01-14 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition and methods of uses
CA3034032C (en) * 2016-08-19 2021-05-25 Foresee Pharmaceuticals Co., Ltd. Compositions comprising inhibitors of macrophage elastase and cyclodextrin
CN109142420B (zh) * 2018-10-12 2020-01-10 厦门大学 基于核磁共振技术探究药物在胶束内最大增溶量的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4434163A (en) 1981-06-01 1984-02-28 Pfizer Inc. Water-soluble benzothiazine dioxide salts
IT1196033B (it) 1984-02-22 1988-11-10 Chiesi Farma Spa Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche
JPS632929A (ja) * 1986-06-20 1988-01-07 Kao Corp アセチルサリチル酸製剤
CA1321192C (en) * 1988-04-20 1993-08-10 Abdul Majid Inclusion complexes of cyclodextrins by agglomeration
KR920006911B1 (ko) * 1989-06-14 1992-08-22 신풍제약 주식회사 안정한 피록시캄 주사액 조성물 및 그의 제조방법
IT1241088B (it) 1990-03-27 1993-12-29 Chiesi Farma Spa Procedimento per la preparazione di complessi piroxicam/ciclodestrina,prodotti ottenuti e loro composizioni farmaceutiche
EP0543886B1 (en) * 1990-08-13 1996-10-30 Commonwealth Scientific And Industrial Research Organisation Pesticidal products
EP1004318A3 (en) * 1991-06-21 2002-08-07 Takeda Chemical Industries, Ltd. Cyclodextrin composition
AT400674B (de) 1991-07-24 1996-02-26 Biochemie Gmbh Pharmazeutische pleuromutilin-zubereitung
IT1293764B1 (it) 1997-07-23 1999-03-10 Chiesi Farma Spa Composizioni farmaceutiche sotto forma di compresse effervescenti contenenti un principio attivo instabile in presenza di acqua
PT1018340E (pt) 1999-01-06 2003-12-31 Tecnimede Sociedade Tecnico Medicinal Sa Complexos de inclusao de sais de aminoacidos de derivados do benzimidazol com ciclodextrinas, sua preparacao e formulacoes farmaceuticas que os contem
FR2815540B1 (fr) * 2000-10-19 2005-06-10 Separex Sa Procede de fabrication de tres fines particules constituees d'un principe insere dans une molecule hote
WO2002089851A1 (fr) * 2001-03-06 2002-11-14 Separex (Societe Anonyme) Procede de fabrication de complexes hote-client
FR2830760B1 (fr) * 2001-10-12 2004-06-04 Pf Medicament Procede de preparation d'un compose d'interaction de substances actives avec un support poreux par fluide supercritique
FR2830761B1 (fr) 2001-10-12 2003-12-12 Pf Medicament Procede de preparation d'un compose d'interaction d'un derive anilide avec un support poreux par fluide supercritique
EP1467715B1 (en) * 2002-01-15 2010-11-03 Ucb Farchim S.A. Formulations for oral administration of active compounds
ATE359827T1 (de) * 2002-06-17 2007-05-15 Chiesi Farma Spa Prozess für die vorbereitung von piroxicam: beta- cyclodextrin einschlusskomplexe
FR2854079B1 (fr) * 2003-04-25 2007-11-30 Pf Medicament Procede de preparation de complexes moleculaires
WO2005112637A1 (en) * 2004-05-14 2005-12-01 Decode Chemistry, Inc. Formulations for non-parenteral use including hydrophobic cyclodextrins

Also Published As

Publication number Publication date
PT2260871E (pt) 2013-08-01
AR049488A1 (es) 2006-08-09
SI2260871T1 (sl) 2013-09-30
PL1729813T3 (pl) 2011-09-30
RU2006138488A (ru) 2008-05-10
US20070270379A1 (en) 2007-11-22
EP2260871A2 (fr) 2010-12-15
US8461133B2 (en) 2013-06-11
EP2260871B1 (fr) 2013-05-15
BRPI0509482B1 (pt) 2018-12-11
CY1114198T1 (el) 2016-08-31
JP2007530641A (ja) 2007-11-01
CA2563101A1 (fr) 2005-10-20
PL2260871T3 (pl) 2013-10-31
DE602005027333D1 (de) 2011-05-19
DK2260871T3 (da) 2013-08-26
JP5091661B2 (ja) 2012-12-05
WO2005097201A3 (fr) 2006-08-17
ATE504316T1 (de) 2011-04-15
WO2005097201A2 (fr) 2005-10-20
EP1729813B1 (fr) 2011-04-06
EP1729813A2 (fr) 2006-12-13
CA2563101C (fr) 2013-07-02
PT1729813E (pt) 2011-07-12
EP2260871A3 (fr) 2011-05-18
US9243076B2 (en) 2016-01-26
ES2424235T3 (es) 2013-09-30
RU2382654C2 (ru) 2010-02-27
US20130316975A1 (en) 2013-11-28

Similar Documents

Publication Publication Date Title
Fu et al. Label-free colorimetric sensor for ultrasensitive detection of heparin based on color quenching of gold nanorods by graphene oxide
BRPI0215331B8 (pt) composições aquosas contendo metronidazol
AU2003250901A1 (en) Compositions and methods for treating a subterranean formation
Schumann et al. Nucleophile‐Directed Stereocontrol Over Glycosylations Using Geminal‐Difluorinated Nucleophiles
AR108998A2 (es) Composición farmacéutica que contiene neurotoxina botulínica
ATE388690T1 (de) Stabilisierung aktiver wirkstoffe durch formulierung als nanopartikuläre zusammensetzungen
MXPA03006071A (es) Preparaciones de ciclodextrina.
BRPI1006790B8 (pt) método para desenvolver uma composição farmacêutica líquida a ser aplicada na pele como uma espuma e composição adequada para uso tópico
WO2008008797A3 (en) Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides
CO5611168A2 (es) Biomateriales novedosos, su preparacion y su uso
WO2005048930A3 (en) Surfactant-based gel as an injectable, sustained drug delivery vehicle
NO20063029L (no) Fremgangsmate for skumming av en hydrokarbonborevaeske og for produksjon av lette hydrokarbonfluider
BRPI0411045A (pt) polìmeros de politioéter lìquidos sob baixa temperatura, composição curável e processo de preparar os mesmos
AU2002212412A1 (en) Method for making very fine particles consisting of a principle inserted in a host molecule
DE602006004719D1 (de) Verfahren zur herstellung von cellulosesulfat mit verbesserten eigenschaften
BRPI0509659A8 (pt) Processo para a preparação de uma composição de polímero de dispersão aquosa
BRPI0605798A (pt) método para fabricação de um agente de absorção de água em partìculas e agente de absorção de água em partìculas
AR053737A1 (es) Formulacion pediatrica de topiramato
ATE551381T1 (de) Verfahren zur herstellung von hochkonzentrierte pelletierte additivkonzentrate für polymer
WO2008019861A3 (de) Verfahren zum lösen geladener nukleinsäure in einer organischen flüssigkeit
NO20055467L (no) Fremgangsmate til fremstilling av molekylaere komplekser
PT1729813E (pt) Complexos de inclusão obtidos utilizando um processo com co2 supercrítico e um agente de interacção com o complexo
BR0203416A (pt) Processo para o revestimento antibiótico de corpos com microcavidades interconectantes bem como corpos revestidos e seu emprego
CY1109541T1 (el) Φαρμακευτικη συνταγοποιηση για την θεραπεια οστεοαρθριτιδας η οποια περιεχει κλοδρονικο οξυ και υαλουρονικο οξυ
CN105473150B (zh) 硼-硅烷聚醚络合物

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C08B 37/16 (2006.01), A61K 31/5415 (2006.01), A61K

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/5415 (2006.01), A61K 47/69 (2017.01), C08B

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/12/2018, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: REFERENTE AO DESPACHO 21.6 PUBLICADO NA RPI 2560 DE 2020-01-28